Search the Newsreel

Here's How to Play NuScale Stock Before Q2 Earnings Release

NuScale Power Corporation SMR is slated to release second-quarter 2026 results on Aug. 5, after market close. The Zacks Consensus Estimate for revenues is pegged at $1 million, implying a decrease of 87.6% from the year-ago quarter. The consensus mark of -$0.13 per share …

Supernus jumps premarket on merger deal; GameStop drops

Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stocks attempted to extend their recovery following July's sharp …

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

Faruqi & Faruqi, LLP is investigating potential claims against Agenus Inc. (NASDAQ: AGEN) and is reminding investors of the November 5, 2024, deadline to seek the role of lead plaintiff in a federal securities class action. The investigation follows a significant drop in Agenus's …

At a glance: stocks gapping up premarket

[Wall Street New York City] aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-up moves before the bell on Monday. Stock index futures were higher on Monday as investors looked forward to a busy week of corporate earnings …

Supernus Pharmaceuticals Reports 32% Second-Quarter 2026 Revenue Growth, Raises Full-Year Guidance and Announces Merger with Indivior

Supernus Announces Second Quarter 2026 Financial Results

Supernus Pharmaceuticals, Inc. Total revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $175.7 million in the second quarter 2026, representing an increase of 52% …

Supernus, Indivior merge to beef up brain drug portfolio

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Brain drug developers Supernus and Indivior on Monday announced plans to merge, bringing together two companies specializing in drugs for …

Supernus Pharmaceuticals Reports 32% Second-Quarter 2026 Revenue Growth, Raises Full-Year Guidance and Announces Merger with Indivior | SUPN Stock News

Supernus and Indivior Agree to All-Stock Merger of Equals

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive agreement to merge in an all-stock, tax-free transaction, creating a U.S. biopharmaceutical company focused on central nervous system (CNS) diseases. The combined entity will be headquartered in Rockville, Maryland, with Supernus CEO Jack A. …

Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results, Misses Estimates By $1.43 EPS

This article provides an overview of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights key metrics such as market capitalization, earnings per share, revenue, and EBITDA, while also offering insights into the company's …

Why Supernus Pharmaceuticals Stock Topped the Market Today

Key Points The two companies will carry the Supernus name. Supernus also published its latest quarterly earnings release.10 stocks we like better than Supernus Pharmaceuticals › Supernus Pharmaceuticals (NASDAQ: SUPN) began the stock trading week on a high note, announcing a major merger alongside …

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9% Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 32.4% year on year to $219.1 million. The company's full-year revenue guidance of $875 …

ELSA Gelontorkan Rp100 Miliar, Buyback Saham Dimulai Hari Ini

NuScale Power (NYSE: SMR) Earnings Report Could Reverse A 50% Stock Decline

NuScale Power Corporation (SMR) has filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The report details the financial condition and results of operations, highlighting a significant increase in outstanding Class A shares due to a completed at-the-market program …

Takeovers Panel declines to probe Cygnus Metals takeover deal

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock, tax-free transaction to create a leading diversified central nervous system (CNS) biopharmaceutical company. The combined entity, to be named Supernus, Inc., is expected to have approximately $2.2 billion in annual revenues and generate $125 …

Understanding Momentum Shifts in (SUPN)

This article analyzes Supernus Pharmaceuticals Inc. (SUPN) using AI models, highlighting a neutral near-term sentiment and potential mid-term weakness. It identifies a breakdown underway, suggesting lower levels and elevated downside risk. The report provides specific institutional trading strategies, including long, breakout, and short positions, …

Energy Giant Elnusa Surges 29% in First-Half Profit, Eyes Bold Expansion into Oil Field Operations

VENUS REMEDIES LIMITED (VENUSREM-EQ.NS) recent insider transactions

Nu Skin Enterprises (NUS) Expected to Announce Quarterly Earnings on Sunday

NuScale Power's Next Earnings Report on Aug. 5 Could Send the Stock Soaring. Here's Why.

NuScale Power Corporation (SMR) has filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The report details the financial condition and results of operations, highlighting a significant increase in outstanding Class A shares due to a completed at-the-market program …

Supernus Pharmaceuticals (SUPN) awards 2,500 performance share units

Supernus Pharmaceuticals' Sr. VP of IP, CSO Padmanabh P. Bhatt, was awarded 2,500 Performance Share Units on July 29, 2026. These units, which were part of an award from February 19, 2025, vested upon the achievement of individual performance objectives set on May 3, …

Janus International Group, Inc. (NYSE:JBI) Given Consensus Rating of "Hold" by Brokerages

Janus International Group (NYSE:JBI) has received a consensus "Hold" rating from brokerages, with an average 12-month price target of $8.33. The stock recently opened at $5.14, trading significantly below its 52-week high, and is down 4.2%. Despite a 5.8% year-over-year revenue increase to $222.7 …

Supernus Pharmaceuticals (NASDAQ: SUPN) CEO granted 29,849 performance share units

Supernus Pharmaceuticals CEO Jack A. Khattar was granted 29,849 Performance Share Units on July 29, 2026, which correspond to one share of common stock each. These units, awarded on February 19, 2025, vested upon the achievement of individual performance objectives established on May 3, …

Agenus (NASDAQ:AGEN) Stock Rating Upgraded by Wall Street Zen

Elnusa Perkuat Kepercayaan Investor Lewat Program Buyback Saham Rp100 Miliar

NuScale Power (SMR) Gains Fresh SMR Backing, Is A $100 Fair Value Credible?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why NuScale Power Stock Is Back in Focus NuScale Power (SMR) is drawing fresh attention after Tennessee Valley Authority and ENTRA1 Energy outlined plans …

AGEN|Agenus Inc|Price:7.500|Chg%:-0.410

TradingKey provides a comprehensive stock analysis for Agenus Inc (AGEN), highlighting its stable fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The analysis notes high institutional ownership and recent "Buy" ratings from analysts with a target price …

This Historic 6-Gigawatt SMR Program Could Be a Game Changer for NuScale Stock

For over three years, NuScale Power (NYSE: SMR) has enjoyed the first-mover advantage of having a small modular reactor (SMR) with Nuclear Regulatory Commission (NRC) certification. What's been missing from NuScale's story, however, is a customer committed to deploying commercial reactors. For NuScale investors, …

Prediction: Buying NuScale Right Now Could Make You Richer by 2036

Key Points AI, data centers, EVs, and electrification could create a substantial market for NuScale's reactors. NuScale has two potential projects, and the completion of either one could help validate its technology. Once NuScale has deployed an SMR commercially, it could inspire confidence and …

Oklo vs. NuScale vs. Bloom Energy: Which AI-Power Stock Is the Better Buy Now?

To feed the never-ending hunger of artificial intelligence (AI) data centers, big tech companies are seeking alternative solutions beyond relying on traditional power grids. Bloom Energy (NYSE: BE) offers a solution, with its solid oxide technology that provides on-site power. Other sources of power …

Vanguard Capital Management (JBI) discloses 6.89M-share passive stake in Janus

Vanguard Capital Management LLC and its affiliates have reported a passive ownership of 6,887,889 shares in Janus International Group Inc., constituting 5.05% of the company's common stock. This Schedule 13G filing indicates that Vanguard exercises sole voting power over 1,021,614 shares and sole dispositive …

Magnus Concordia Reschedules AGM and Adjusts Shareholder Book Closure

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Amphastar Pharmaceuticals (AMPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare …

Venus Metals Corporation Limited Reports Earnings Results for the Full Year Ended June 30, 2026

Oklo vs. NuScale: Which One Actually Has Paying Customers Lined Up?

Oklo (NYSE: OKLO) and NuScale Power (NYSE: SMR) remain two of the most popular nuclear energy stocks. However, there's a good reason why excitement about both companies has waned in the past year. Neither company has made much progress exiting the pre-revenue stage. Oklo …